

LUD 5466,4 - JEL/NDH (09807811)

The specification has been amended, thereby addressing point 5; however, the request regarding page 26 will not be carried out. The test which proceeds the table explains the reiteration fully.

Point 6 is not understood.

In points 7 and 8, claims 1, 3, 9 and 57-59 have been rejected under 35 USC § 112, first paragraph as allegedly not satisfying the written description requirement. Claim 2 was not so rejected.

Claim 74 combines claims 1 and 2, and thus should clearly be deemed free of this rejection. Claim 75 correspond to prior claim 3, depends from claim 74, and is thus free of the rejection. Claims 76 and 77 correspond to prior claims 4 and 5, which were not so rejected, and thus are free of the rejection. Claim 78 correspond to old claim 9, depends from claim 74, and is thus free of the rejection. Claim 79 correspond to prior claim 10, and is free of the rejection. Claims 80 and 81 correspond to old claims 14 and 15. Claims 55-58 are canceled, with no replacement claims. Claim 59 is replaced by claim 82. The claim requires SEQ ID NO: 7, as well as a peptide which must be found in a given sequence, and which correspond to the peptide defined by claim 74. Claim 84 correspond to claim 60, not rejected under 35 USC § 112, first paragraph.

The spelling changes obviates the rejections at point 10.


Only claims 55-58 were rejected under 35 USC § 103. These claims have been canceled and will be pursued in a divisional application.

All rejections have been addressed, and overcome.

As the amendment rests on a combination of a base claim and a claim which had been rejected solely due to the use of "polypeptide"/"peptide" and lack of uniformity therein, and a spelling error, any further rejections will be treated as non-final rejections.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By 

Norman D. Hanson
Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3000